Boehringer Ingelheim and Eli Lilly's SGLT2 inhibitor Jardiance has been approved for chronic kidney disease in the EU - the first major market to clear the new use for the drug. Adding CKD to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results